Stock 603998 HUNAN FANGSHENG PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

All News Hunan Fangsheng Pharmaceutical Co., Ltd.

Equities

603998

CNE100001VG6

End-of-day quote Shanghai S.E.
Other stock markets
 18:00:00 2024-06-13 EDT 		5-day change 1st Jan Change
10.88 CNY -0.55% Intraday chart for Hunan Fangsheng Pharmaceutical Co., Ltd. -2.33% -0.73%
04-19 Hunan Fangsheng Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
04-10 Fangsheng Pharma's Factories Pass GMP Inspection MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Hunan Fangsheng Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Fangsheng Pharma's Factories Pass GMP Inspection
MT
Fangsheng Pharma Gets 12.1 Million Yuan in Government Grants in January-March
MT
Fangsheng Pharma Withdraws Drug Registration Application For Headache Treatment
MT
Hunan Fangsheng Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
CI
Hunan Fangsheng Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
CI
Hunan Fangsheng Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Fangsheng Pharma's Drugs Placed in 2022 Chinese Drug Catalogue
MT
Hunan Fangsheng Pharmaceutical Sees Up to 357% Surge in 2022 Profit; Shares Jump 3%
MT
Hunan Fangsheng Pharma Unit to Resume Work After Leakage Forces Suspension
MT
Hunan Fangsheng Pharmaceutical's Chinese Medicine Extraction Line Passes Regulatory Inspection
MT
Hunan Fangsheng Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022
CI
Hunan Fangsheng Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022
CI
Hunan Fangsheng Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
Hunan Fangsheng Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021
CI
Hunan Fangsheng Pharmaceutical Co., Ltd. announced that it expects to receive CNY 269.999999 million in funding
CI
Hunan Fangsheng Pharmaceutical Co., Ltd. announced a financing transaction
CI
Hunan Fangsheng Ruixin Pharmaceutical Co., Ltd. announced that it expects to receive CNY 160 million in funding from Hunan Fangsheng Pharmaceutical Co., Ltd., Changsha Xingchen Kangrui Venture Capital Partnership Enterprise (Limited Partnership), and another investor
CI
China shares end lower as rising local COVID-19 cases drag consumer firms
RE
Guo Jianjun agree to acquire 50% stake in Hunan Hengxing Pharmaceutical Technology Co., Ltd. from Hunan Fangsheng Pharmaceutical Co., Ltd. for CNY 9.4 million.
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 603998 Stock
  4. News Hunan Fangsheng Pharmaceutical Co., Ltd.